Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset
Project # Project Title Research Focus Area Research Program Administering IC Institution(s) Investigator(s) Location(s) Year Awarded
1R43DA060033-01A1
Xylazine and opioid overdose mitigation therapy using decoy receptor biomimetic nanoparticles, NarcoBond platform Cross-Cutting Research Small Business Programs NIDA CIBOTS, INC. ESMAELI-AZAD, BABAK San Diego, CA 2024
NOFO Title: PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-23-230
3K23DA055695-03S1
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: A Pilot Randomized Controlled Trial Training the Next Generation of Researchers in HEAL NIDA RHODE ISLAND HOSPITAL BERK, JUSTIN Providence, RI 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
3R01DA057668-01S1
Enhancing Precision in Overdose Mortality Prediction through Data Linkage: A Heterogeneous Capture-Recapture Approach to Estimating Opioid Use Disorder Prevalence in Ohio Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDA OHIO STATE UNIVERSITY FERNANDEZ, SOLEDAD A (contact); FAREED, NALEEF Columbus, OH 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
3UG1DA013732-25S1
CTN - Evaluation of SeMaglutide as an Adjunct to buprenorphine treatment for the treatment of opioid use disorder: A pragmatic Randomized placebo-controlled Trial (SMART) Translation of Research to Practice for the Treatment of Opioid Addiction Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids NIDA UNIVERSITY OF CINCINNATI WINHUSEN, T JOHN Cincinnati, OH 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
3UG1DA013732-25S2
CTN - Effects of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro and Zepbound) on incidence and outcomes of stimulant use disorders and opioid use disorder in real-world populations: target tr Translation of Research to Practice for the Treatment of Opioid Addiction Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids NIDA UNIVERSITY OF CINCINNATI WINHUSEN, T JOHN Cincinnati, OH 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
3UG1DA015831-23S1
EMS initiated Buprenorphine for Opioid Use Disorder Translation of Research to Practice for the Treatment of Opioid Addiction Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids NIDA YALE UNIVERSITY D'ONOFRIO, GAIL (contact); CARROLL, GERARD; HSER, YIH-ING; KEATING, ELIZABETH New Haven, CT 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
3UG1DA013720-25S2
Low-threshold buprenorphine treatment at syringe services programs: a Type I hybrid effectiveness-implementation trial” (CTN concept under development) Translation of Research to Practice for the Treatment of Opioid Addiction Enhancing the National Drug Abuse Treatment Clinical Trials Network to Address Opioids NIDA UNIVERSITY OF MIAMI SCHOOL OF MEDICINE SZAPOCZNIK, JOSE (contact); FEASTER, DANIEL J; METSCH, LISA R Coral Gables, FL 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
3U24DA055325-04S2
The Healthy Brain and Child Development National Consortium Administrative Core Enhanced Outcomes for Infants and Children Exposed to Opioids HEALthy Brain and Child Development (HBCD) Study NIDA UNIVERSITY OF CALIFORNIA SAN DIEGO CHAMBERS, CHRISTINA (contact); NELSON, CHARLES ALEXANDER La Jolla, CA 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
3U24DA055330-04S1
Healthy Brain and Child Development National Consortium Data Coordinating Center Enhanced Outcomes for Infants and Children Exposed to Opioids HEALthy Brain and Child Development (HBCD) Study NIDA WASHINGTON UNIVERSITY IN ST. LOUIS SMYSER, CHRISTOPHER DANIEL (contact); DALE, ANDERS M; FAIR, DAMIEN A St. Louis, MO 2024
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-20-272
1R34DA059770-01
Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform New Strategies to Prevent and Treat Opioid Addiction NIDA FRIENDS RESEARCH INSTITUTE, INC. TOFIGHI, BABAK (contact); LEKAS, HELEN-MARIA; LEWIS, CRYSTAL FULLER Baltimore, MD 2024
NOFO Title: Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional)
NOFO Number: PA-21-110
1R43DA058603-01A1
Developing a novel epigenetic regulator as a treatment for opioid use disorder Cross-Cutting Research Small Business Programs NIDA EPIVARIO, LLC KIM, THOMAS Philadelphia, PA 2024
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176
3R34DA057639-02S1
Diversity Supplement: Leveraging Parents and Peer Recovery Supports to Increase Recovery Capital in Emerging Adults with Polysubstance Use: Feasibility, Acceptability, and Scaling Up of Launch Training the Next Generation of Researchers in HEAL NIDA CHESTNUT HEALTH SYSTEMS, INC. DRAZDOWSKI, TESS K Normal, IL 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3R01DA056675-01S1
Domain-specific inhibition of angiotensin-converting enzyme as a therapeutic strategy for opioid use disorders Training the Next Generation of Researchers in HEAL NIDA UNIVERSITY OF MINNESOTA ROTHWELL, PATRICK (contact); MORE, SWATI S Minneapolis, MN 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3U01DA055363-04S1
The Transgenerational Influence of Discrimination on Mental Health Training the Next Generation of Researchers in HEAL NIDA OREGON HEALTH & SCIENCE UNIVERSITY SULLIVAN, ELINOR L (contact); GRAHAM, ALICE M Portland, OR 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3U2CDA057717-03S1
Use of topic modeling and stakeholderengagement to map determinants of implementation disparities in addiction and pain research Training the Next Generation of Researchers in HEAL NIDA STANFORD UNIVERSITY MCGOVERN, MARK P (contact); BECKER, SARA; BECKER, WILLIAM C; BROWN, C HENDRICKS Redwood City, CA 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3R33DA057747-04S1
The influence of neighborhood factors and social determinants of health on OUD treatment outcomes Training the Next Generation of Researchers in HEAL NIDA UNIVERSITY OF MARYLAND MAGIDSON, JESSICA F College Park, MD 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3R01DA057599-01S1
Diversity Supplement for Mining Social Media Big Data for Toxicovigilance Training the Next Generation of Researchers in HEAL NIDA EMORY UNIVERSITY SARKER, ABEED H Atlanta, GA 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3R34DA057604-01S1
Research supplement to promote diversity within the context of research involving recovery community centers Training the Next Generation of Researchers in HEAL NIDA MASSACHUSETTS GENERAL HOSPITAL HOEPPNER, BETTINA B Somerville, MA 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3U01DA055355-04S1
9/24- Healthy Brain and Child Development National Consortium Training the Next Generation of Researchers in HEAL NIDA NORTHWESTERN UNIVERSITY CHICAGO WAKSCHLAG, LAUREN S (contact); NORTON, ELIZABETH SPENCER Chicago, IL 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
3U01DA055316-04S2
16/24 Healthy Brain and Child Development National Consortium HEAL Diversity Supplement Training the Next Generation of Researchers in HEAL NIDA UNIVERSITY OF MARYLAND FOX, NATHAN A (contact); HARDEN, BRENDA J; RIGGINS, TRACY L College Park, MD 2024
NOFO Title: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp Clinical Trial Not Allowed)
NOFO Number: PA-23-189
1UG3DA059278-01A1
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA SPARIAN BIOSCIENCES, INC. REICH, JEFFREY New York, NY 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200
1U01DA059994-01
Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA BIOCORRX PHARMACEUTICALS, INC. DEVARNEY, KATE BEEBE Anaheim, CA 2024
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
NOFO Number: PAR-22-202
1UG3DA061620-01
Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA USWM, LLC MASSEY, VERONICA LYNCH (contact); SCHMIDT, LEE Louisville, KY 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200
1U01DA060708-01
Phase III double-blind, randomized controlled trial of suvorexant versus placebo to treat insomnia in persons with opioid use disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA JOHNS HOPKINS UNIVERSITY HUHN, ANDREW S Baltimore, MD 2024
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
NOFO Number: PAR-22-202
1UG3DA060053-01
Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA GILGAMESH PHARMACEUTICALS, INC. MAREK, GERARD JOSEPH New York, NY 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200